PTIE enrolls PTI-901 Phase III

Pain Therapeutics (PTIE) completed enrollment of 600 women in a U.S. double-blind, placebo-controlled Phase III trial of PTI-901 naltrexone to treat irritable bowel syndrome (IBS). The primary endpoin...